India

Zydus Cadila

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Zydus Cadila Receives Final Approval from the Usfda for Cisatracurium Besylate Injection

Lead Product(s): Cisatracurium Besylate

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 02, 2020

Details:

Zydus Cadila has received final approval from the USFDA to market Cisatracurium Besylate Injection USP (US RLD: Nimbex ®) in the strength of 20 mg (base)/10 mL (2 mg/mL) Multiple-Dose Vial.

Premier Intermediates Pvt.Ltd.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Baudax Bio Awarded Group Purchasing Agreement with Premier Inc. for ANJESO®

Lead Product(s): Meloxicam

Therapeutic Area: Neurology Product Name: Anjeso

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Baudax Bio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement August 25, 2020

Details:

The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for ANJESO (meloxicam) injection, for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.

Glenmark

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Glenmark Pharmaceuticals gets USFDA nod for Fingolimod capsules

Lead Product(s): Fingolimod

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 19, 2020

Details:

United States Food & Drug Administration (U.S. FDA) for Fingolimod Capsules, 0.5 mg, the generic versionof Gilenya®1Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Zydus Cadila

Zydus Cadila Receives Final Approval from the Usfda for Cisatracurium Besylate Injection

Premier Intermediates Pvt.Ltd.

Baudax Bio Awarded Group Purchasing Agreement with Premier Inc. for ANJESO®

Glenmark

Glenmark Pharmaceuticals gets USFDA nod for Fingolimod capsules